Levosimendan improves contractility in vivo and in vitro in a rodent model of post-myocardial infarction heart failure

Acta Physiol (Oxf). 2014 Apr;210(4):865-74. doi: 10.1111/apha.12248.

Abstract

Aim: As few studies have presented a thorough analysis of the effect of levosimendan (LEV) on contractility, our purpose was to investigate in vivo cardiac function as well as in vitro cardiomyocyte function and calcium (Ca(2+) ) handling following LEV treatment.

Methods: Rats with post-myocardial infarction heart failure (HF) induced by ligation of the left anterior descending coronary artery and sham-operated animals were randomized to the infusion of LEV (2.4 μg kg(-1) min(-1) ) or vehicle for 40 min. Echocardiographic examination was coupled to pressure-volume sampling in the left ventricle before (B) and after (40 min) infusion. Isolated left ventricular cardiomyocytes were studied in an epifluorescence microscope.

Results: HF LEV (n = 6), HF vehicle (n = 7), sham LEV (n = 5) and sham vehicle (n = 6) animals were included. LEV infusion compared to vehicle in HF animals reduced left ventricular end-diastolic pressure and mean arterial pressure (both P < 0.001) and improved the slope of the preload-recruitable stroke work (P < 0.05). Administrating LEV to HF cardiomyocytes in vitro improved fractional shortening and Ca(2+) sensitivity index ratio, and increased the diastolic Ca(2+) (all P < 0.01).

Conclusion: In HF animals, LEV improved the contractility by increasing the Ca(2+) sensitivity. Furthermore loading conditions were changed, and LEV could consequently change organ perfusion. An observed increase in diastolic Ca(2+) following LEV treatment and clinical implications of this should be further addressed.

Keywords: Ca2+ sensitivity; Ca2+ transients; contractility; heart failure; inotropic drug; preload.

MeSH terms

  • Animals
  • Calcium
  • Cardiotonic Agents / therapeutic use*
  • Female
  • Heart Failure / drug therapy*
  • Heart Failure / etiology
  • Hydrazones / therapeutic use*
  • Myocardial Infarction / complications*
  • Pyridazines / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Simendan

Substances

  • Cardiotonic Agents
  • Hydrazones
  • Pyridazines
  • Simendan
  • Calcium